Skip to content
MarketScale
‹ Back to IndustriesSciences

Forging Connections: Flipping CAPA on Its Head with Prevention

Waste and lost money run rampant in various sectors, and healthcare and pharmaceuticals are no exception. Bethany Kearney, Director of Enablement for Sparta Systems, and Zillery Fortner, Product Advisor, QA/RA Life Sciences at Sparta Systems, joined Forging Connections Host Michelle Dawn Mooney to discuss flipping corrective and preventive action (CAPA) on its head through preventive…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Healthcare · KappaMedical DevicesPharmaceuticalsRecall
Share

Key takeaways

01

Waste and lost money run rampant in various sectors, and healthcare and pharmaceuticals are no exception.

02

Bethany Kearney, Director of Enablement for Sparta Systems, and Zillery Fortner, Product Advisor, QA/RA Life Sciences at Sparta Systems, joined Forging Connections Host Michelle Dawn Mooney to discuss flipping corrective and preventive action (CAPA) on its head through preventive…

Waste and lost money run rampant in various sectors, and healthcare and pharmaceuticals are no exception. Bethany Kearney, Director of Enablement for Sparta Systems, and Zillery Fortner, Product Advisor, QA/RA Life Sciences at Sparta Systems, joined Forging Connections Host Michelle Dawn Mooney to discuss flipping corrective and preventive action (CAPA) on its head through preventive measures.

Fortner provided an example of how reusable medical devices like gowns would rip after 40 uses or so when they were supposed to last for 100 lifecycles. The safety complaints stopped at a high level instead of digging down deep to find the root cause. Issues were accredited to “human error” or incorrect repair. “There wasn’t global communication between the different facilities. There were multiple issues going on. Multiple times it was closed in CAPA, saying it was fixed. When it came down to it, the true root cause was a chemical reaction,” Fortner stated. Addressing the actual cause would have saved millions of dollars.

“Finding the true root cause is very complex. It’s easy to blame a human, and if the firm is 100 percent focused on metrics, then finding the true root cause is going to be very challenging. Because in some cases, it is costly,” Kearney explained. She added, “It’s much more costly to not know that true root cause,” and that “putting in the time to do it right is really where the value is.”

The key is to follow the seven steps of the CAPA process. Fortner listed them as identifying the problem, evaluating the problem, developing and investigating, analyzing the problem, creating an action plan, implementing it, and analyzing the effectiveness.

Fortner added that prevention is essential, and companies should plan, do, check, act…Lacking support from the right stakeholders will cause you to struggle and make the process difficult. It is also imperative not to play the blame game and to understand why the mistake happened, fix it, and ensure the fix works.

When CAPAs go awry, this can cause incredibly costly issues. “A recall is just one part of doing something wrong or not really, truly understanding the problem,” stated Fortner. “A recall process can cost up to 600 million dollars, according to research from McKinsey. The medical device industry spends around 5 billion dollars a year on recalls. This expense we can’t ignore because lives are at risk. Every minute that a defective product stays out on the market is another opportunity for someone to be injured.”

“The payoff to doing CAPA right, I don’t think you can measure,” stated Fortner.

For more podcasts from Forging Connections, visit Apple iTunes or Spotify.

About the author

H
Healthcare

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512